About Supriya Lifescience Ltd
Supriya Lifesciences is primarily engaged in manufacturing of Bulk Drugs and Pharmaceutical Chemicals.
Founded
2008
CEO
Satish Waman Wagh
Employees
1,071
HQ
Mumbai, Maharashtra
Finished Products
1Export Sales
₹1,146.64Cr2Domestic Sales
₹252.39Cr3Foreign Currency Fluctuation G
₹12.24Cr4Duty drawback received
₹10.77Cr5RODTEP Incentives
₹6.84CrRaw Materials
1Cost of Material Consumed
₹423.87CrAbout Supriya Lifescience Ltd
Supriya Lifesciences is primarily engaged in manufacturing of Bulk Drugs and Pharmaceutical Chemicals.
Founded:2008
CEO:Satish Waman Wagh
Employees:1,071
HQ:Mumbai, Maharashtra
Finished Products
1Export Sales
₹1,146.64Cr2Domestic Sales
₹252.39Cr3Foreign Currency Fluctuation G
₹12.24Cr4Duty drawback received
₹10.77Cr5RODTEP Incentives
₹6.84CrRaw Materials
1Cost of Material Consumed
₹423.87CrPrice Performance & Market EventsPrice Performance
Loading chart data…
Key Metrics
Trading & valuation snapshot
52W High
₹1,085
52W Low
₹546
Volume960.56K
Avg VolumeN/A
Beta0.69
Dividend Yield0.12%
Key Financial Ratios
Profitability, leverage & efficiency at a glance
P/E Ratio
32.55x
Valuation
P/B Ratio
5.39x
Valuation
EPS
₹24.65
Valuation
Dividend Yield
0.12%
Valuation
ROE
17.46%
Profitability
ROCE
23.00%
Profitability
Revenue by Segment
Contribution & growth by business line
No segment revenue data available
Geographical Revenue Split
Domestic vs international exposure
Domestic
0.0%
International
0.0%
No geographic split data available
Strategic Relations
Collaborations, joint ventures & subsidiaries
No collaborations data available.
Forensic Metrics
Financial health & earnings-quality indicators
Revenue Quality
N/A
Days Sales Outstanding
Leverage
0.00x
Debt-to-Equity
Earnings Quality
N/A
Cash Conversion Ratio
Efficiency
N/A
Asset Turnover
Earnings Quality
N/A
Accruals Ratio
Profitability
N/A
Gross Margin
Growth
14.8%
Sales Growth
These metrics are derived from available financial disclosures and market data. Use them together with company filings and qualitative analysis before making decisions.